Novel irreversible EGFR tyrosine kinase inhibitor 324674 sensitizes human colon carcinoma HT29 and SW480 cells to apoptosis by blocking the EGFR pathway

Biochemical and Biophysical Research Communications

Volumn 411, Issue 4, 2011, Pages 751-756

  Yu, Zhiwei ^a   Cui, Binbin ^a   Jin, Yinghu ^a   Chen, Haipeng ^a   Wang, Xishan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Colorectal cancer; EGFR; Irreversible EGFR inhibitor 326474; Proliferation

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR 324674; GW 583340; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL ASSAY; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANILIDES; APOPTOSIS; CARCINOMA; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HT29 CELLS; HUMANS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TYRPHOSTINS;

EID: 80051556379     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.07.019     Document Type: Article

References (31)

1. Khamly K., Jefford M., Michael M., et al. Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer. Expert Opin. Invest. Drugs 2005, 14:607-628.
2. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5:341-354.
3. Vallbohmer D., Lenz H.J. Epidermal growth factor receptor as a target for chemotherapy. Clin. Colorectal Cancer 2005, 5:19-27.
4. Cunningham M.P., Essapen S., Thomas H., et al. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int. J. Oncol. 2005, 27:317-325.
5. Cohen S., Carpenter G., King L. Epidermal growth factor-receptor protein kinase interactions: co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J. Biol. Chem. 1980, 255:4834-4842.
6. Damjanov N., Meropol N.J. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?. Oncology (Huntingt) 2004, 18:479-488.
7. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 2002, 20(Suppl.):1S-13S.
8. Grandis J.R., Sok J.C. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol. Ther. 2004, 102:37-46.
9. Saltz L.B., Meropol N.J., Loehrer P.J., Needle M.N., Kopit J., Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 581:201-1208.
10. Chu E. Cetuximab targeted therapy: a new treatment paradigm for advanced colorectal cancer. Clin. Colorectal Cancer 2004, 3:205-215.
11. Yin Y.M., Geng Y.T., Shao Y.F., Hu X.L., Li W., Shu Y.Q., Wang Z.X. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer. J. Exp. Clin. Cancer Res. 2010, 29(1):126.
12. Baselga J., Rischin D., Ranson M., Calvert H., Raymond E., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 2002, 20:4292-4302.
13. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352(8):876-892.
14. Yu Z.W., Boggon T.J., Kobayashi S., Jin C., Ma P.C., Sowlati A., Kern J.A., Tenen D.G., Halmos B. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res. 2007, 67(21):10417-10427.
15. Diasio R.B., Fourie J. Targeting the epidermal growth factor receptor in the treatment of colorectal cancer. Drugs 2006, 66:1441-1463.
16. Downward J., Parker P., Waterfield M.D. Autophosphorylation sites on the epidermal growth factor receptor. Nature 1984, 311(5985):483.
17. Oda K., Matsuoka Y., Funahashi A., Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 2005, 1:0010. Epub 2005, May 25.
18. Marmor M.D., Skaria K.B., Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58:903-913.
19. Wakeling A.E. Inhibitors of growth factor signaling. Endocr. Relat. Cancer 2005, 12:S183-S187.
20. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008, 358:1160-1174.
21. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351:337-345.
22. Hida T., Ogawa S., Park J.C., Park J.Y., Shimizu J., Horio Y., et al. Gefitinib for the treatment of non-small-cell lung cancer. Expert Rev. Anticancer Ther. 2009, 9:17-35.
23. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N. Engl. J. Med. 2005, 353:133-144.
24. Gravalos C., Cassinello J., Garcia-Alfonso P., Jimeno A. Integration of panitumumab into the treatment of colorectal cancer. Crit. Rev. Oncol. Hematol. 2009, (Epub ahead of print).
25. Ryan Q., Ibrahim A., Cohen M.N., Hohnson H., Ko C.W., Sridharra R., et al. Fda drug approval summary. Lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008, 13:1114-1119.
26. Nautiyal J., Rishi A.K., Majumdar A.P. Emerging therapies in gastrointestinal cancers. World J. Gastroenterol. 2006, 12:7440-7450.
27. Zhang H., Berezov A., Wang Q., Zhang G., Drebin J., Murali R., et al. ErbB receptors: from oncogenes to targeted cancer therapies. J. Clin. Invest. 2007, 117:2051-2058.
28. Zhou Y.F., Li S., Hu Y., Wang J., et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res. 2006, 66:404-411.
29. Rusnak D.W., Lackey K., Affleck K., et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 2001, 1:85-94.
30. Wakeling A.E. For a review of EGFR kinase inhibitors that have been in the clinic. Curr. Opin. Pharmacol. 2002, 2:382-387.
31. Wissner Allan, Mansour Tarek S. The development of HKI-272 and related compounds for the treatment of cancer. Arch. Pharm. Chem. Life Sci. 2008, 341:465-477.